Kornimate/medical-research-clean huggingface dataset:
allogenic mesenchymal stem cell derived exosome in patients with acute ischemic stroke

Conditions: Cerebrovascular Disorders

Summary: administration of cell-free exosomes derived from mesenchymal stem cell (mscs) can be sufficient to exert therapeutic effects of intact mscs after brain injury. in this study we aim to assay the administration of msc derived exosome on improvement of disability of patients with acute ischemic stroke

exosomes derived from multipotent mesenchymal stromal cells (mscs) promote neurovascular remodeling and functional recovery after stroke. animal study has shown that exosome treatment markedly increased the number of newly formed doublecortin (a marker of neuroblasts) and von willebrand factor (a marker of endothelial cells) cells. based on previous literature, intravenous administration of msc-generated exosomes post stroke improves functional recovery and enhances neurite remodeling, neurogenesis, and angiogenesis and represents a novel treatment for stroke. also some studies have presented which mir-124-loaded exosomes ameliorate the brain injury by promoting neurogenesis. so in present study we aim to assess improving patients with acute ischemic stroke who received msc derived exosome

Eligibility criteria:
inclusion criteria: * male or female acute ischemic patients aged 40-80 years with symptoms of acute cerebral infarction of less than 24h from stroke onset. * patients with infarct size 3\*3 * patients with a measurable focal neurological that must persist to the time of treatment without clinically meaningful improvement. * patients must have computerized tomography (ct) and / or magnetic resonance imaging (mri) compatible with the clinical diagnosis of acute ischemic stroke in the territory of the middle cerebral artery before being included in the study. * patients must have a score on the nih stroke scale 8-24, and mrs ≤ 1 * women of childbearing age should have a negative pregnancy test performed prior to inclusion * obtaining informed consent signed exclusion criteria: comatose patients. * brain tumour, cerebral oedema with compression of ventricles, cerebellar infarction or brainstem, or intraventricular, intracerebral or subarachnoid haemorrhage. * alcohol use active infectious disease, including hiv, hepatitis b, hepatitis . * patients with dementia. * specify clinical conditions * patients who are participating in another clinical trial. * inability or unwillingness of individual for giving written informed consent.
dapagliflozin evaluation on atrial fibrillation patients followed cox maze iv procedure

Conditions: Atrial Fibrillation Recurrence; Cox Maze IV; Atrial Fibrillation; Patients With or Without Heart Failure and Diabetes

Summary: atrial fibrillation (af) is the most common arrhythmia, which leads to reduced cardiac output and promotes the occurrence of heart failure, and abnormal hemodynamic changes in the left atrium induce thrombosis, which seriously reduces the quality of life, and even leads to death. for patients who need cardiac surgery combined with the cox-maze iv (cmiv) surgical ablation, oral amiodarone postoperatively for three consecutive months was recommended as the preferred treatment option. however, the study found there were still 15%-35% of patients at risk of af recurrence. dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has been widely used for the treatment of type 2 diabetes mellitus and heart failure. nonetheless, it remains unknown whether dapagliflozin can improve the recurrence of af and reduces adverse cardiovascular events for patients who need cmiv ablation, and whether it can be routinely used for af patients without diabetes or heart failure. therefore, this study aims to explore the effect of postoperative oral dapagliflozin on the recurrence of af after cmiv.


Eligibility criteria:
inclusion criteria: * age ≥18 years * patients with persistent or long-term persistent atrial fibrillation who need isolated surgical cox-maze iv procedure * patients who need cardiac surgery combined with cox-maze iv procedure * patients who have the ability and willingness to abide by all the subsequent reviews and requirements * sign the informed consent exclusion criteria: * dapagliflozin allergy * hyperthyroidism * patients with acute myocardial infarction, cerebral apoplexy, and other vascular diseases during the past 6 months * patients who received heart surgery within the last 3 months * egfr\<45ml/min * history of oral sglt2i * estimated survival period \< 12 months * pregnant and lactating women * left atrial diameter \> 65 mm * refusing to sign the informed consent
stem cells and stromal vascular fraction for temporomandibular joint disease

Conditions: Temporomandibular Joint Disorders; Temporomandibular Disorder; Temporomandibular Joint Osteoarthritis; Temporomandibular Joint Pain; Temporomandibular Joint Effusion

Summary: it will be evaluate the safety of mesenchymal stem cells and adipose tissue derived stromal vascular fraction (svf) in temporomandibular joint disease cases.

umbilical cord derived mesenchymal stem cells produced under gmp facility in erciyes university and svf produced in operation theatre.

Eligibility criteria:
inclusion criteria: * chronic temporomandibular arthritic disorder * history of pain and joint noises for at least 3 months * must have more than vas 5 tmj pain * must have internal derangement of tmj * limited mouth opening * magnetic resonance imaging evidence of effusion or degeneration * already treated with conservative methods (occlusal splint,pharmacological and/or physio-kinesio therapy) without satisfactory benefit. exclusion criteria: * cancer patients * immunosupressed patients * previous tmj traumas and fractures * previous tmj surgeries * tmj ankylosis
effectiveness of a barbershop-based program to improve high blood pressure control and awareness in black men

Conditions: Hypertension

Summary: black men in the united states have a greater risk of developing high blood pressure than men of any other ethnic or racial group. the purpose of this study is to evaluate the effectiveness of a high blood pressure detection and medical referral program conducted by barbers in predominantly black barbershops at increasing awareness and lowering blood pressure levels among their black male customers.

high blood pressure affects approximately 35% of black men in the united states. this may be due to the fact that black men frequently have an unusually high number of risk factors for high blood pressure, including diabetes, high stress levels, and increased salt intake and sensitivity. while high blood pressure can often be controlled through diet, lifestyle changes, or medication, it is a chronic asymptomatic medical condition for which individuals should remain under the care of a regular medical provider. a predominantly black barbershop may be an optimum and receptive setting for an intervention that focuses on improving the detection and treatment of high blood pressure among black men. in this study, barbers, deemed as influential peers, will be trained to continually monitor their customers' blood pressure, deliver health messages designed to change risk perception and ideas about healthcare utilization, and provide social support for changes in healthcare-seeking behavior and blood pressure levels. the purpose of this study is to evaluate the effectiveness of a barbershop-based intervention at increasing blood pressure awareness and lowering blood pressure levels among black male customers. with over 18,000 black barbershops in the united states, the results from this study may be extremely influential in improving the diagnosis and treatment of high blood pressure in black men. this study will enroll black men who are regular customers at a participating barbershop. each barbershop will be randomly assigned to either a 10-month intervention group or a control group. nurses will train the intervention group barbers to measure blood pressure and deliver health messages related to blood pressure control during each customer's visit. before and after the intervention, study researchers will interview barbers and customers over an 8-week period to collect information on blood pressure control. a 12-month follow-up visit will include assessments of blood pressure levels, customer recognition of elevated blood pressure levels, and the number of customers receiving regular medical care.

Eligibility criteria:
inclusion criteria: * african american * regular customer at one of the participating barbershops exclusion criteria: * does not speak english

Keywords: blood pressure, high blacks african americans
health-related quality of life in gay men with localized prostate cancer

Conditions: Prostate Cancer

Summary: rationale: gathering information about prostate cancer, treatment, and quality of life from gay men with prostate cancer may help doctors plan the best treatment. purpose: this clinical trial is collecting information about health-related quality of life from gay men with localized prostate cancer.

objectives: * to enroll 200 gay men with localized prostate cancer in a cross-sectional study of prostate cancer outcomes. * to complete an r01 application using pilot data collected from these patients. * to complete manuscripts describing the factors that influence quality of life and treatment satisfaction in these patients. outline: patients complete a web-based survey about their disease (biopsy gleason score, psa at diagnosis, and t-stage), treatment (treatment type, time since treatment, and use of healthcare services \[e.g., oral medications for erectile dysfunction\]), symptom distress, and psychosocial factors (ethnicity, health literacy, level of social support, communication with provider, relationship status, and communication with partner) that affect their health-related quality of life. the data will be used to provide the information necessary to tailor an existing prostate cancer survivorship intervention to address the specific needs of gay men with prostate cancer.

Eligibility criteria:
disease characteristics: * diagnosis of localized prostate cancer * no advanced disease * self-identified as gay patient characteristics: * able to complete an online questionnaire * able to speak and understand english prior concurrent therapy: * not specified

Keywords: stage i prostate cancer stage ii prostate cancer
influence of oral vitamin c supplement on the inflammation status in dialysis patients

Conditions: Uremia; Inflammation

Summary: subclinical inflammation is a common phenomenon in patients receiving maintenance hemodialysis (mhd). this is because various pro-inflammatory cytokines are promoted due to metabolic acidosis, volume overload, and / or non-sterile dialysate. as important antioxidants, vitamin c was prominently consumed by oxidative stress and inflammation. so patients receiving dialysis therapy usually had a low plasma vitamin c level. it was documented that inflammation was associated with increased risk of cardiovascular morbidity and mortality in patients on dialysis. but the relationship between plasma vitamin c and each of inflammatory markers and prealbumin was lacking. because vitamin c had anti-inflammation effect on behalf of its electron receiving ability, the investigators made a hypothesis that vitamin c supplementation can reduce inflammation status in patients on maintenance dialysis

objective a cross-over study is designed to elucidate if oral vitamin c supplementation can reduce inflammation status in maintenance dialysis patients with low vitamin c level and high crp level. patients, methods and expected results patients about 100 dialysis patients were recruited. patients will be divided into two groups, and will be followed for at least 6 months. methods arm 1(50cases): is given oral vitamin c 200mg per day in the first 3 months, then stop oral vitc for the next 3 months. arm 2(50cases): is not given vitamin c in the first 3 months, then switch to receive oral vitc 200mg per day in the next 3 months. the demographics were recorded. plasma vitamin c was measured by high-performance liquid chromatography. serum albumin, prealbumin, high-sensitivity c-reactive protein (hscrp), ferritin, hemoglobin will be measured. expected results there may be positive effect of vitamin c supplementation on inflammation in maintenance dialysis patients with vitamin c deficiency and high crp level.

Eligibility criteria:
inclusion criteria: * patients receiving maintenance hemodialysis or continuous ambulatory peritoneal dialysis, and dialysis vintage more than 3 months * patients aged between 18 and 80 years older * vitc \ 3mg/l * for hd patients, kt/v \> 1.2 per session, at least 3 sessions per week, 4 hours per session * for pd patients, kt/v \> 1.7 per week * age and gender matched health control exclusion criteria: * active autoimmune disease, malignancy, hepatitis * positive hiv serology * any kind of acute infection within one month, chronic infection * currently using steroids or immune-suppressants * pregnancy or breast feeding

Keywords: dialysis,inflammation,vitamin c
tocilizumab vs azathioprine in neuromyelitis optica spectrum disorders

Conditions: Neuromyelitis Optica Spectrum Disorders; Neuromyelitis Optica

Summary: in neuromyelitis optica spectrum disorder (nmosd),interleukin-6 (il-6) may play an important role in facilitating plasma cells to produce pathological aquaporin 4 (aqp4) autoantibody. inhibition of il-6 signaling pathway by tocilizumab (actemra®), a humanized monoclonal antibody may have shown beneficial clinical effects in a few patients with nmosd. larger scale clincial trials may be needed to observe its efficacy and safety. here, by choosing azathioprine, one of the most frequently used medication in case of relapses, the investigators compare the safety and efficacy of tocilizumab in preventing nmosd attacks.

the investigators primarily aim to observe the time to first relapse from initiation of tocilizumab or azathioprine treatment. the proportion of participants who experience relapse-free in one year follow-up will be compared. the secondary outcomes are to determine: the safety profile of tocilizumab and azathioprine in participants with nmo and whether tocilizumab improves visual function, expanded disability status scale (edss), et al.

Eligibility criteria:
inclusion criteria: 1. male or female patients ≥ 18 years old 2. diagnosis of nmo or nmo spectrum disorder 3. clinical evidence of at least 2 relapses in last 12 months or 3 relapses in the last 24 months 4. able and willing to give written informed consent and comply with the requirements of the study protocol. 5. edss \<= 7.5 (8 in special circumstances) 6. men and women of reproductive potential must agree to use a highly effective method of birth control from screening to 6 months after final dose of the investigational product. exclusion criteria: 1. current evidence or known history of clinically significant infection (herpes simplex virus, varicella-zoster virus, cytomegalovirus, epstein-barr virus,human immunodeficiency virus, hepatitis viruses, syphilis, etc) 2. pregnant, breastfeeding, or child-bearing potential during the course of the study 3. patients will not participate in any other clinical therapeutic study or will not have participated in any other experimental treatment study within 30 days of screening 4. participation in another interventional trial within the last 3 months 5. heart or kidney insufficiency 6. tumor disease currently or within last 5 years 7. clinically relevant liver, kidney or bone marrow function disorder 8. intolerance of azathioprine or previous relapses on azathioprine treatment 9. receipt of rituximab or any experimental b-cell depleting agent within 6 months prior screening and b-cells below the lower limit of normal.
long-term follow-up of participants treated with galapagos chimeric antigen receptor (car) t-cell therapies

Conditions: Hematological Malignancies

Summary: this is a long-term follow-up study for participants treated with galapagos (glpg) car t-cell therapies to evaluate the long-term safety and efficacy of glpg car t-cell products for 15 years post infusion. per health authorities guidelines for gene therapy medicinal products that utilize integrating vectors (e.g. lentiviral vectors), long term safety and efficacy follow up of treated patients is required. the purpose of this study is to monitor all participants exposed to glpg car t-cell therapies for 15 years following their last car t-cell infusion to assess the risk of delayed adverse events (aes) and the long-term benefit/risk profile and to monitor for replication-competent lentivirus (rcl) and car-t cell persistence.


Eligibility criteria:
inclusion criteria: * all participants who have been treated with a galapagos car t-cell therapy in a clinical trial or managed access program. exclusion criteria: * there are no exclusion criteria for this study

Keywords: car t-cell therapy
effect of leo 39652 cream in adults with mild to moderate atopic dermatitis (ad)

Conditions: Atopic Dermatitis

Summary: the aim of this trial is to assess the efficacy of leo 39652 cream compared with leo 39652 cream vehicle in adults with mild to moderate ad after 3 weeks of treatment.


Eligibility criteria:
inclusion criteria: * subjects with atopic dermatitis (ad) as defined by hanifin and rajka criteria and with mild to moderate disease severity (iga 2 or 3) * two symmetrical and comparable entire treatment areas, on the same body region (left and right part) * subjects must be in good health * female subjects of childbearing potential and male subjects must be willing to consent to using high effective methods of contraception exclusion criteria: * any condition in the treatment areas that in the opinion of the investigator could interfere with clinical assessments, e.g. acne, infection, rash (other than atopic dermatitis), sunburn, hyper-or hypopigmentation, scars * dark-skinned persons (i.e. skin type iv to vi according to fitzpatrick classification system) whose skin colour prevents reliable clinical assessments * any permanent (or transient within 28 days prior to dosing) disease (in particular cardiac disease such as heart failure or history of myocardial infarction) that may interfere with the subjects safe participation in the trial, with the subjects ability to participate in the trial or with the clinical assessments * subjects with congenital or acquired immunodeficiencies or in subjects on therapy that causes immunosuppression
the effect of chinese herbal formula (ksy) on hcv carrier with abnormal liver function

Conditions: Liver Function

Summary: the aim of the study is to examine whether the chinese herbal formula (ksy) is effective on hcv carrier with abnormal liver function.

percentage of change on hcv rna titer and liver function (gpt).

Eligibility criteria:
inclusion criteria: * 40 \< gpt \<200 hcv carrier age: 18-65 yrs old exclusion criteria: * creatinine \>2.0 mg/dl total bilirubin \> 2.0mg/dl not suitable patients diagnosis by physician in charge.

Keywords: hcv carrier chinese herbal medicine liver function hcv rna titer
michigan medicine covid-19 cohort: clinical characteristics, inflammatory markers and outcomes of patients hospitalized for covid-19

Conditions: Covid19; Kidney Diseases; Inflammation; SARS-CoV Infection

Summary: to better understand the role of inflammation in covid-19, we established the michigan medicine covid-19 cohort (m2c2). m2c2 is a funded and ongoing cohort which has currently enrolled over 1500 adult patients (≥18 years) with severe covid-19 admitted at the university of michigan. the purpose of m2c2 is to define the in-hospital course of these patients and understand the role of inflammation as a determinant of organ injury and outcomes in covid-19.

the michigan medicine covid-19 cohort is a prospective observational cohort study of patients hospitalized specifically for covid-19 at the university of michigan health system in ann arbor. medical records of all consecutive patients with a positive sars-cov-2 are reviewed, and patients with confirmed sars-cov-2 infection but not primarily admitted for covid-19 were excluded. biologic samples of patients enrolled in m2c2 were collected, and clinical characteristics including in-hospital outcomes were characterized in detail. biomarkers measured include, but not be limited to, soluble urokinase plasminogen activator receptor (supar), high sensitive c reactive protein (hs-crp), brain natriuretic protein (bnp), high sensitive troponin t (hstnt), interleukin 6 (il-6), osteopontin, a2-antiplasmin.

Eligibility criteria:
inclusion criteria: * confirmed sars-cov-2 infection * hospitalized primarily for the treatment of covid-19 exclusion criteria: * sars-cov-2 positive but hospitalized for non-covid-19 reasons

Keywords: biomarkers outcomes inflammation supar c-reactive protein interleukin-6
pilot study of nursing touch and biobehavioral stress

Conditions: Prematurity; Stress Reaction

Summary: randomized cross-over clinical trial to determine the effect of a nurse-administered comforting touch intervention on the biobehavioral stress responses of preterm infants hospitalized in the neonatal intensive care unit.

preterm infants will receive one episode of essential nursing care as standard care and one episode of essential nursing care that includes a nurse-administered comforting touch intervention approximately 24 hours apart in a randomized sequence. for 10 minutes prior to the start of the two observed care episodes, during the care episodes, and for 60 minutes after the conclusion of the care episodes, researchers will measure infants' biobehavioral stress responses. when infants reach 35 weeks post-menstrual age, researchers will perform a neurobehavioral assessment.

Eligibility criteria:
inclusion criteria: * born prematurely between 27 and 30 weeks post-menstrual age. * born to mothers who are english-speaking and able to provide informed consent. * no more than 10 days old at the time of enrollment. exclusion criteria: * diagnosed with grade iii/iv intraventricular hemorrhage or other neurologic abnormality (e.g. seizure disorder) affecting sensory perception or motor function. * diagnosed with a congenital anomaly requiring surgery during the neonatal period. * receiving scheduled steroids or vasopressors. * skin conditions that preclude the attachment of sensors. * diagnosed with neonatal abstinence syndrome or born to mothers with known illicit drug use, except marijuana, during pregnancy. * diagnosed with chromosomal abnormalities. * requiring special isolation with universal gloving for potentially infectious pathogens.

Keywords: preterm infant stress nursing care touch
circulating human papilloma virus (hpv) dna for the screening and surveillance of gynecologic cancers

Conditions: Cervical Dysplasia; Cervical Cancer

Summary: human papilloma virus-related gynecologic malignancies affect over 20,000 women in the united states, and over half a million women globally each year. in addition, approximately 200,000 women are diagnosed with high-grade cervical dysplasia, a pre-cancerous tumor. there is no currently available serum biomarker for these tumors, and surveillance and diagnosis in these patients often requires invasive testing and procedures. the ability to diagnose and monitor for these cancers with a simple blood draw would have a significant impact both here in the us and abroad. in order to detect circulating tumor-specific hpv dna, the investigators will collaborate with the molecular diagnostics company, naveris. naveris has designed a blood test that utilizes digital droplet polymerase chain reactions (pcr) in order to quantify fragments of tumor-specific dna that the investigators believe is shed by hpv-associated cancer cells in the blood. in this pilot study, the investigators will first test whether the quantification of plasma cell-free hpv dna can distinguish pre-invasive from invasive cervical cancers.


Eligibility criteria:
inclusion criteria: all patients above age 18, with biopsy proven hpv-related high-grade cervical dysplasia or invasive cervical cancer will be included. exclusion criteria: persons who do not meet the above inclusion criteria.